ASPIRE

ASPIRE will create a novel imaging biomarker for dementia for diagnosis support. Signs of Alzheimer’s (AD) will be detectable at early stages before clinical manifestation. The solution is based on the non-invasive magnetic resonance imaging (MRI) technique “Arterial Spin Labelling” (ASL) combined with scanner calibration,
physiological atlas comparison, and artificial intelligence (AI)-based diagnostic support. The technique will simplify the diagnostic process, reduce cost and patient risk.